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1. Introduction 
Assembly of a complex polysaccharide via a cyclic 
pathway involving polyprenol lipid-linked inter- 
mediates was first demonstrated in the case of 
peptidoglycan biosynthesis [l] and there is now con- 
siderable evidence that at least some of the glyco- 
proteins of eukaryotic cells are glycosylatedvia similar 
intermediates [2-71. Halobacterium salinarium has 
a high molecular weight glycoprotein as its major 
surface component [ 8,9] and has recently been 
shown to have enzymatic activities for formation of 
lipid-linked sugars of the type expected as inter- 
mediates if glycosylation of the glycoprotein occurs 
via a polyprenol lipid carrier [lo] . Despite the fact 
that Halobacteria lack a peptidoglycan layer their 
growth is inhibited by bacitracin [ 1 l] , an antibiotic 
which inhibits growth of normal bacteria by com- 
plexing with the Css isoprenyl pyrophosphate 
released upon transfer of the newly formed subunit 
to the growing peptidoglycan chain [ 12,131. Forma- 
tion of this complex prevents the enzymatic dephos- 
phorylation of the lipid which is necessary for it 
again to act as an acceptor and allow continued 
peptidoglycan synthesis. The effects of bacitracin on 
H. salinarium have been examined and this report 
describes experiments which provide further evidence 
that glycosylation of the surface glycoprotein occurs 
via a cyclic pathway involving lipid intermediates. 
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2. Materials and methods 
Bacitracin was obtained from The Upjohn Co. 
(Kalamazoo, MI). UDP-N-acetyl-[r4C]glucosamine 
(269 mCi/mmol) was obtained from Amersham 
Searle and L- [ 35 S] methionine and sodium [‘*PI - 
phosphate (carrier-free) from New England Nuclear. 
Growth, harvesting and cell envelope preparation 
of Halobacterium salinarium, strain 1, were as in [ 81. 
[3sS]Methionine-labeling of cells was done in a 
defined medium [ 141 originally described [ 151 with 
the exception that the methionine concentration was 
reduced from 2.5-0.25 mM. This concentration 
was sufficient to allow normal growth and approx. 
12% of the radioactivity was incorporated by the cells. 
Phospholipids were labeled by growing cells in the 
normal growth medium [8] to which approx. 
50 &i/ml of sodium [‘*PI phosphate was added. 
Carbohydrates were determined by calorimetric 
assays as in [9] . Protein was determined as in [ 161. 
Thin-layer chromatography of lipids and carotenoids 
was done on precoated plates of Silica Gel F-254 
(Merck). Solvents A and B were chloroform : 
methanol : water (65:35:6) and (65:25:4) and C was 
2,6-dimethyWheptanone : acetic acid:water (8:5:1). 
3. Results 
When bacitracin is added to growing cultures of 
H. salinarium, cell growth continues for approximately 
one doubling time and a gradual change from normal 
rod-shaped to spherical cells occurs [ 1 l] . The surface 
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glycoprotein is the major shape-maintaining com- 
ponent of the cell envelope [ 171, suggesting that 
bacitracin may act by altering its synthesis or com- 
position. The proteins of cells grown in the presence 
of [3sS]methionine were examined in order to deter- 
mine if the glycoprotein continues to be made and if 
it is present to the same extent in both normal and 
bacitracin-treated cells. 
Labeling was begun 2 h after addition of bacitracin 
to the treated culture and was continued for 24 h 
(fig.1). At the end of this time all (> 98%) of the cells 
grown in the presence of bacitracin were spherical 
and all of the untreated cells were rod-shaped. 
Labeled cells were then harvested and washed in 
[35S]methionine-free medium. The final cell pellet 
then solubilized in 2% SDS and the proteins were 
2oc 
IO< 
5( 
IC 
I- 
>- 
I- 
/ 
-s-+6-- 
Hours 
Fig. 1. Growth CUIV~S and [ ” S] methionine labeling of 
untreated (A) and bacitracin-treated (B) cells. Growth was 
determined using a Klett photometer with a red filter. Baci- 
tracin was added to culture B at final cont. 25 pg/ml. [s’s]- 
Methionine (approx. 18 &i) was added to both cultures 2 h 
later. Untreated cells incorporated approx. 12% added label 
and treated cells approx. 6%. 
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Fig.2. Proteins of [35S]methionine-labeled H. sulinotiwn. 
Proteins of cells grown and labeled as shown in fig. 1 were 
electrophoresed on SDS-polyacrylamide slab gels using the 
gel system in [ 181 with a 3% acrylamide stacking gel and a 
7.5% acrylamide running gel. Shown are densitometry scans 
of autoradiograms of dried gels of (A) untreated cells and 
(B) cells grown in the presence of bacitracin. The glycoprotein 
is labeled G and the dotted line is included to illustrate the 
slightly higher mobility of the glycoprotein in treated cells. 
Quantitation of radioactivity was done by slicing bands from 
the gels, incubating overnight at 30°C in 10 ml toluene 
scintillation fluid containing 3% protosol (New England 
Nuclear) and counting in a liquid scintillation counter. 
Identical results were obtained when samples were run on 
tube gels and sliced and counted as in [ 81. 
examined by SDS-polyacrylamide gel electrophoresis 
(fig.2). The glycoprotein accounted for l l-13% 
total radioactivity in the proteins of both untreated 
and bacitracin-treated cells. Thus, while bacitracin 
inhibited cell growth and caused a morphological 
change it did not selectively inhibit synthesis of the 
glycoprotein. 
Although the glycoprotein was present to the same 
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extent in normal and treated cells, its migration during 
SDS-polyacrylamide gel electrophoresis indicated 
that it might have an altered composition in treated 
cells. The glycoprotein of treated cells has a slightly 
higher mobility (fig.2 and [ 171) consistent with it 
having a decreased carbohydrate content. Purification 
by aqueous phenol extraction was attempted in order 
to obtain the altered glycoprotein for further charac- 
terization. This procedure results in separation of the 
normal glycoprotein, which remains in the aqueous 
phase, from the other cell envelope proteins which 
are extracted into the phenol phase [8,9] . However, 
when envelopes from bacitracin-treated cells were 
extracted, the glycoprotein was found in the phenol 
phase along with the other envelope proteins. A 
decreased carbohydrate content would explain the 
failure of the altered glycoprotein to partition into 
the aqueous phase. 
Due to the fact that the glycoprotein accounts for 
all of the non-lipid carbohydrate of the cell envelope 
[8] it has been possible to demonstrate that baci- 
tracin treatment results in decreased glycosylation 
despite the inability to isolate the altered glycoprotein 
from treated cells. 25% neutral hexose in the cell 
envelope is present in (2 : 1) chloroform:methanol- 
extractable glycolipids [8]. The other 75% of the 
hexose and all of the amino sugar is attached to the 
glycoprotein in the form of a single N-linked hetero- 
saccharide containing amino sugars and hexoses and 
34-38 O-linked di- and tri-saccharides containing 
neutral hexoses and hexuronic acid [9]. Lipid-free 
envelopes from bacitracin-treated cells showed 
significant decreases in all of the carbohydrates in 
comparison to envelopes of untreated cells (table 1). 
These results, together with the evidence that the 
glycoprotein continues to be synthesized and is 
present to the same extent in normal and treated 
cells, demonstrate that growth in the presence of 
bacitracin results in inhibition of glycosylation of the 
glycoprotein. The greater decrease in amino sugar 
than in hexose or uranic acid suggests that synthesis 
and/or attachment of the N-linked heterosaccharide 
is affected to a greater extent than is that of the 
O-linked units. 
The other major envelope components have been 
examined in order to determine if bacitracin affects 
only the glycoprotein. These include the remaining 
proteins (approx. 32% envelope dry wt) and the 
lipids (approx. 2 1% envelope dry wt) [8]. It was 
previously shown that no changes in the envelope 
proteins, other than the glycoprotein, are detectable 
by SDS-polyacrylamide gel electrophoresis ([ 161 
and fig.2). No significant difference in the total 
amount of glycolipid was found between untreated 
and treated cells (table 1). No differences in lipid 
composition were detected when total lipid extracts 
(CHCla : MeOH, 2: 1) were compared by thin-layer 
chromatography on silica gel in solvent systems A, 
B and C followed by iodine staining. Similarly, no 
differences in major phospholipids were detected 
when cells were labeled with 32P and the lipids 
examined by thin-layer chromatography in solvent 
systems A, B and C, followed by autoradiography. 
TWO very minor phospholipids (accounting for less 
Table 1 
The effect of bacitracin on cell-envelope carbohydrate contenta 
(rmol/lOO mg envelope protein) 
Amino sugar Hexose Uranic acid Glycolipid hexose 
Untreatedb 7.9 f 0.6 35.6 * 0.6 17 f 2 10.3 r 0.2 
Bacitracinb 4.0 f 0.6 24 ~2 10.5 f 0.3 9.7 r 0.3 
treated 
% decrease 49 32 38 6 
a Isolated cell envelopes were extracted 3 times with CHCl, :MeOH (2: 1) and the 
lipid-free cell envelopes assayed for protein and carbohydrate content as in 
section 2. Extracted lipids were evaporated to dryness, redissolved in CHCl,:MeOH 
(2: 1) and aliquots assayed 
bBacitracin (25 &ml) was added to the treated cultures 12 h after inoculation and 
control and treated cells harvested 24 h later 
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than 0.5% total radioactivity) were greatly decreased 
or absent in bacitracin-treated cells. The possible 
nature of these will be discussed below. 
The carotenoids present in the envelope of 
H. salinarium [19] were also examined in treated and 
untreated cells. In vitro synthesis of compounds 
whose biosynthetic pathways involve polyprenol 
pyrophosphate intermediates, as is the case for caro- 
tenoids, is inhibited by bacitracin [20,21] , presum- 
ably due to complex formation between bacitracin 
and the polyprenol pyrophosphate precursors. No 
differences in either carotenoid content (measured as 
A units/mg envelope protein) or in the absorption 
spectra of the carotenoids (fig.3) was found between 
untreated and bacitracin-treated H salinarium. There 
were also no differences between treated and untreated 
cells in the mobilities of the three major carotenoids 
on silica gel in solvent systems A, B and C. These 
results indicate that bacitracin is unable to enter the 
cell and suggest hat its action in inhibiting glycosyla- 
tion of the glycoprotein occurs at the cell surface. 
The absence of two minor phospholipids in 
bacitracin-treated cells might be explained by the 
inability of these cells to form the lipid intermediates 
for glycosylation due to all polyprenol being in the 
pyrophosphate form complexed with bacitracin. This 
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Fig.3. Absorption spectra of carotenouds from (-o-o-) normal 
and (-o- -o-) bacitracin treated cells. Cells were grown and 
treated as shown in fig.1. Cell envelopes were extracted with 
CHCl,:MeOH, (2: 1) and the extracts dried and redissolved 
in CHCl,:MeOH (1:l) at cont. equiv. 0.67 mg cell-envelope 
protein/ml. 
Table 2 
Formation of C,,,_,, isoprenyl pyrophospho-N- 
acetylglucosamine by cell homogenates of untreated and 
bacitracin-treated cells 
pm01 amino sugar incor- 
porated/100 mg protein 
Untreated 4.7 .+ 0.3 
Bacitracin-treatedb 0.8 + 0.3 
Untreated + bacitracinC 4.8 * 0.3 
a Cell homogenates were prepared and assayed as in [ 101. 
Reaction mixture was final vol. 0.25 ml and UDP-N-acetyl- 
[‘4C]glucosamine was added at final cont. 1.5 PM 
b Cells were grown and treated as shown in fig. 1 and 
harvested 20 h after the addition of bacitracin (25 pg/ml) 
to the culture 
’ Bacitracin was added to the normal cell homogenate 
reaction mixture at final cont. 25 pg/ml prior to addition 
of the UDP-N-acetyl-[ “Clglucosamine 
possibility was tested more directly by examining 
lipid-intermediate formation. It was previously shown 
that cell homogenates have enzymatic activities for 
formation of lipid-linked sugar compounds from 
nucleotide sugars and endogenous lipid. In the case of 
UDP-N-acetylglucosamine, the only product formed 
is C55_-60 isoprenyl pyrophospho-N-acetylglucosamine. 
As expected if bacitracin is acting by blocking a cyclic 
lipid carrier pathway, formation of this compound 
was greatly reduced (75-900/o) in cells grown in the 
presence of bacitracin (table 2). That transfer of the 
sugar from the Cs5-a lipid to an acceptor with 
release of lipid pyrophosphate does not occur under 
in vitro assay conditions [lo] . Addition of bacitracin 
to a homogenate of untreated cells should therefore 
not affect formation of the N-acetylglucosamine 
lipid and the results shown in table 2 confirm this. 
4. Discussion 
The effects of bacitracin described here, together 
with the results of studies of the formation of lipid- 
linked sugar compounds [lo] , suggest hat formation 
of the N-linked heterosaccharide of the H. salinarium 
surface glycoprotein occurs via a cyclic pathway 
involving lipid-linked intermediates. The hetero- 
saccharide is apparently formed at the cytoplasmic 
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side of the membrane by sequential transfer of sugars 
to the lipid carrier from substrates available in the 
cytoplasm. IV-Acetylglucosamine is added first to 
form isoprenyl pyrophospho-N-acetylglucosamine. 
Additional sugars are then attached via glycosidic 
bonds to the growing saccharide chain by transfer 
from either nucleotide diphosphosugars or isoprenyl 
monophospho-sugars [lo] . The heterosaccharide is 
then transferred, at the exterior surface of the cell, to 
the protein acceptor and the resulting lipid pyrophos- 
phate is dephosphorylated to yield the monophos- 
phate which can again act as an acceptor. Bacitracin 
blocks the dephosphorylation, presumably by com- 
plexing with the lipid pyrophosphate at the outer cell 
surface, thus inhibiting further glycosylation. There is 
not sufficient evidence available to allow a conclusion 
as to whether the O-linked di- and tri-saccharides of 
the protein are formed via a similar pathway. Attach- 
ment is via an O-glycosidic linkage between galactose 
and threonine but we have been unable to demon- 
strate either formation of a galactose-lipid compound 
[lo] or direct transfer of galactose from nucleoside 
diphosphogalactose to a deglycosylated acceptor 
protein (unpublished). The decreased amount of 0 
linked carbohydrate on the glycoprotein of cells 
grown in bacitracin (table 1) suggests that lipid inter- 
mediates might be involved but the possibility that 
this decrease is a secondary effect of inhibiting attach- 
ment of the N-linked heterosaccharide cannot be 
ruled out. 
While it is clear that glycosylation of eukaryotic 
glycoproteins can occur via dolichol-linked inter- 
mediates [2-71 it has not been demonstrated that 
this is a major pathway for glycosylation nor that it 
is cyclic. We have been unsuccessful in attempting to 
demonstrate an effect of bacitracin on glycosylation 
of glycoproteins in a human lymphocyte cell line 
grown in vitro despite the fact that bacitracin can 
form a complex with dolichol pyrophosphate 
(P. Parham, M. F. M. and J. Wedgwood, unpublished). 
As is the case with Halobacteria, bacitracin appears to 
be unable to enter the cell, as evidenced by normal 
levels of cholesterol biosynthesis. A likely explana- 
tion for failure to observe an effect of bacitracin on 
glycosylation of lymphocyte glycoproteins is that 
formation and attachment of saccharide units probably 
occurs primarily on the endoplasmic reticulum or in 
the Golgi apparatus rather than at the surface of the 
plasma membrane and that the dolichol pyrophos- 
phate released upon transfer is thus inaccessible to 
binding by bacitracin. 
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